Macrotope
Private Company
Funding information not available
Overview
Macrotope is a private, pre-clinical stage biotech firm pioneering an antigen-centric immunology platform. Its core technology, the patented MAV™ platform, engineers the conformational dynamics of protein antigens to enhance immunogenicity and B-cell engagement, leading to more diverse antibody libraries and improved vaccine candidates. The company is applying this platform to develop next-generation vaccines for infectious diseases like SARS-CoV-2 and to partner on therapeutic antibody discovery projects, with a strong emphasis on design for manufacturability and global health equity.
Technology Platform
Patented MacroAntigen Vaccine (MAV™) discovery engine that engineers antigen conformational dynamics to enhance immunogenicity, broaden B-cell engagement, and generate more diverse antibody libraries, paired with a 'Design for Manufacturability' philosophy.
Opportunities
Risk Factors
Competitive Landscape
Faces competition from large vaccine developers (Pfizer, Moderna), numerous biotechs working on broadly protective coronaviruses vaccines, and a crowded field of antibody discovery platform companies (e.g., using phage display, single B-cell sorting, AI/ML). Differentiation lies in the specific focus on antigen conformational dynamics and design-for-manufacture.